Trial Profile
A Randomized, Open-Label Study of the Effect of PEGASYS [peginterferon alfa-2a] and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naive Patients With Chronic Hepatitis C Genotype 2 or 3 Infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ACCELERATE
- Sponsors Roche
- 20 Oct 2005 New trial record.